Lead Product(s): AEF0117
Therapeutic Area: Psychiatry/Psychology Product Name: AEF0117
Highest Development Status: Phase II Product Type: Small molecule
Deal Size: $130.0 million Upfront Cash: $30.0 million
Deal Type: Collaboration June 08, 2021
Indivior has entered into a strategic collaboration with Aelis Farma ("Aelis"), a private biotechnology company based in Bordeaux, France, that includes an exclusive option and license agreement (the "Agreement") for the global rights to AEF0117.